Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The limbic localization of the arginine vasopressin V 1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V 1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a positive control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V 1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Ethopharmacological analysis of rat behavior on the elevated plus-maze
Cruz, A. P. M., Frei, F., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90472-3 · Cited by 823
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Animal models for the study of anti-anxiety agents: A review
Treit, D. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90046-6 · Cited by 450
Miczek, K. A. (1979) · Psychopharmacology · doi:10.1007/bf00426664 · Cited by 397
De Wled, D. (1965) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(65)90005-5 · Cited by 377
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375
Landgraf, R., Gerstberger, R., Montkowski, A., Probst, J., Wotjak, C., Holsboer, F., & Engelmann, M. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-06-04250.1995 · Cited by 341
Extrapituitary expression of the rat V1b vasopressin receptor gene.
Lolait, S. J., O'Carroll, A. M., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, E., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337
Oxytocin, vasopressin and memory: opposite effects on consolidation and retrieval processes
Bohus, B., Kova´cs, G. L., & De Wied, D. (1978) · Brain Research · doi:10.1016/0006-8993(78)90052-5 · Cited by 311
Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308
Blanchard, R. J., Griebel, G., Andrew Henrie, J., & Caroline Blanchard, D. (1997) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00062-0 · Cited by 276
Self-citationENGELMANN, M., WOTJAK, C. T., NEUMANN, I., LUDWIG, M., & LANDGRAF, R. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00059-3 · Cited by 269
Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211
Self-citationSeptal vasopressin modulates anxiety-related behaviour in rats
Liebsch, G., Wotjak, C. T., Landgraf, R., & Engelmann, M. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13069-x · Cited by 173
Localization of Vasopressin (V1a) Receptor Binding and mRNA in the Rhesus Monkey Brain
Young, Toloczko, & Insel (1999) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1999.00332.x · Cited by 139
Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents.
Misslin, R., Belzung, C., & Vogel, E. (1989) · Behavioural Processes · doi:10.1016/s0376-6357(89)80010-5 · Cited by 98
Behavioral Effects of Neuropeptides: Endorphins and Vasopressin
Koob, G. F., & Bloom, F. E. (1982) · Annual Review of Physiology · doi:10.1146/annurev.ph.44.030182.003035 · Cited by 83
Animal models of human emotion and cognition.
Haug, M., & Whalen, R. E. (1999) · American Psychological Association eBooks · doi:10.1037/10335-000 · Cited by 82
Vasopressin involvement in antipyresis, social communication, and social recognition: a synthesis.
Dantzer, R., & Bluthé, R.-M. (1992) · PubMed · Cited by 55
Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
Simiand, J., Keane, P. E., Barnouin, M. C., Keane, M., Soubrié, P., & Fur, G. L. (1993) · PubMed · Cited by 34
Self-citationEffects of provocation on emotions and aggression in males
Chermack, S. T., Berman, M. E., & Taylor, S. P. (1997) · Aggressive Behavior · doi:10.1002/(sici)1098-2337(1997)23:1<19::aid-ab3>3.0.co;2-o · Cited by 26
The Neurohypophysial Peptides, Learning, and Memory Processinga
Bohus, B., Borrell, J. I., Koolhaas, J. M., Nyakas, C. J., Buwalda, B., Compaan, J. C., & Roozendaal, B. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb55554.x · Cited by 21
Central Behavioral Effects of Vasopressin: Point and Perspectives
Alescio‐Lautier, B., Metzger, D., & Soumireu-Mourat, B. (1993) · Reviews in the Neurosciences · doi:10.1515/revneuro.1993.4.3.239 · Cited by 20
The Mouse Defense Test Battery: An experimental model of different emotional states.
Griebel, G., & Sanger, D. J. (2004) · American Psychological Association eBooks · doi:10.1037/10335-005 · Cited by 10
Self-citationPreservation of a conditioned avoidance response by lysine vasopressin.
de Wied, D. (1970) · PubMed · Cited by 7
Research works printed but not linked: 3
- D De Wied J Endocrinol 48, xlv–xlvi (1970).
- R Dantzer, R M Bluthe Crit Rev Neurobiol 6, 243–255 (1992).
- J Simiand, P E Keane, M C Barnouin, M Keane, P Soubrié, G Le Fur Fundam Clin Pharmacol 7, 413–427 (1993).
Cited by
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
“Because a selective AVPR1B antagonist had anxiolytic- and antidepressant-like effects in rodent”
BackgroundWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605
Fatigue in neurological disorders
Chaudhuri, A., & Behan, P. O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15794-2 · Cited by 1,297
Metadata
- Authors
- Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Affiliations
- Sanofi (France) (FR)
- Sanofi–Synthelabo Recherche, Avenue P. V.-Couturier, 92220 Bagneux, France; Sanofi–Synthelabo Recherche, Route d'Espagne, 31100 Toulouse, France; and Sanofi–Synthelabo Recherche, Rue du Professeur Blayac, 34000 Montpellier, France
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6370-6375
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122955
- OpenAlex
- W2003547326
- Cited by
- 471
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 8 · 2016: 20 · 2015: 18 · 2014: 29 · 2013: 16 · 2012: 21
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- non-peptide antagonists, anxiolytic effects, antidepressant effects, anxiety, depression, chronic mild stress, social defeat, traumatic stress, emotional processing, hypophysectomy, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety, Behavior, Animal, Depression, Feeding Behavior, Fluoxetine, Imipramine, Indoles, Kinetics, Male, Mice, Inbred BALB C, Pyrrolidines, Stress, Physiological, Stress, Psychological, Time Factors, Anti-Anxiety Agents, Rats, Sprague-Dawley, Rats, Wistar, Risk Assessment, Antidepressive Agents, Second-Generation, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.